Insilico Medicine's AI-Generated Drug Reaches Clinical Trials For Lung Disease

Insilico Medicine, a biotech firm based in Abu Dhabi’s Masdar City, has pioneered the creation of the world’s first fully AI-generated drug. This drug, designed to treat idiopathic pulmonary fibrosis (IPF), is now in later-stage clinical trials. While AI has contributed to many pharmaceuticals, Insilico’s drug is unique as it was entirely generated by AI, from identifying the treatment target to designing the drug’s structure.

"This AI drug is a major milestone for us and for the industry as a whole," said Dr. Alex Zhavoronkov, Insilico Medicine’s CEO and an expert in longevity medicine. "We can use AI to create lifesaving treatments for new diseases using approaches we haven’t yet considered, and do so much more rapidly and efficiently. We’re also exploring other applications, such as climate change. Ultimately, our mission is to use generative AI and robotics to extend life and sustain the human race."

Idiopathic pulmonary fibrosis (IPF) is a rare and deadly disease characterized by progressive lung scarring with no known cure and limited treatment options. In the Middle East, it is estimated that up to 60 million people are at risk of developing respiratory diseases, including pulmonary fibrosis.

Insilico scientists utilized their AI platform to identify a new biological "target," or protein, that could be inhibited with a drug to halt or reverse IPF progression. Their findings were published in Nature Biotechnology, detailing how Insilico’s AI platform leveraged the connection between fibrosis and ageing to make this discovery.

Clinical Trials and Future Prospects

Two Phase 2a clinical trials of the AI-generated drug are currently underway in the United States and China. These trials aim to evaluate the drug’s safety, tolerability, and effectiveness in improving lung function. Insilico has over 30 AI-designed drugs in its pipeline, including seven in clinical stages. Several of these have been licensed by leading pharmaceutical companies such as Sanofi, Menarini, and Exelixis.

The UAE Insilico team is also working on further advancements to Insilico’s Pharma.AI platform, including integrating large language models and quantum computing.

Masdar City: A Hub for Innovation

"Insilico Medicine is only one of many AI and biotech organisations in Masdar City that are working to create a healthier, more sustainable future," said Steve Severance, Masdar City’s director of growth. "We’ve developed our ecosystem for exactly this reason – to foster growth, collaboration, and new solutions that move the world forward. Secondcell Bio is using cell engineering to scale its drug discovery processes, and they’re located just a few hundred meters from Insilico’s lab in Masdar City. It’s exciting to see the amazing work our partners are doing."

Earlier this year, Masdar City signed a memorandum of understanding (MOU) with the Abu Dhabi Department of Health and two other biotech companies, Xlife Sciences and Thermo Fisher Scientific. This agreement is part of a strategy to drive growth and innovation in Abu Dhabi’s life sciences sector.

With inputs from WAM